Fish & Richardson Secures Win for Exela Pharma Sciences in ELCYS® Patent Infringement Litigation
Retrieved on:
Monday, August 15, 2022
Health, Patent Law, Professional Services, Pharmaceutical, Legal, FDA, TPN, Technology, Liver disease, PTAB, Topical steroid withdrawal, District, Patent Trial and Appeal Board, Patent, LLC, Research, ANDA, Douglas v. U.S. District Court ex rel Talk America, Patient, Eton, Twitter, Fish & Richardson, District court, PGR, Infant, Parenteral nutrition, Aluminium, Culture, LinkedIn, Adult, Blackburn C.A.15C, Cysteine, Generic drug, Facebook
Fish & Richardson secured a significant victory for Exela Pharma Sciences, LLC, the maker of ELCYS, in patent infringement litigation against Eton Pharmaceuticals, Inc., over its intent to produce a generic version of Exelas patented ELCYS product.
Key Points:
- Fish & Richardson secured a significant victory for Exela Pharma Sciences, LLC, the maker of ELCYS, in patent infringement litigation against Eton Pharmaceuticals, Inc., over its intent to produce a generic version of Exelas patented ELCYS product.
- Fish filed a Hatch-Waxman lawsuit in the District of Delaware on behalf of Exela in March 2020 against Eton.
- Marshaling the scientific evidence through opinion leading industry experts, Fish demonstrated that the patent claims are novel and nonobvious.
- Fish offers patent prosecution, litigation, trademark, and copyright counseling and advocacy for a broad range of client needs.